Thanks to biopharmaceutical company Renovo we could possibly speak of a small revolution in the scar treatment sector.

The leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration aims to be first to market with a scar reduction pharmaceutical drug in the US and Europe.

The product, brand name Juvista, is administered before surgery and is designed to prevent scars. More about this medicine here. The company has successfully trialled a new formulation of Juvista that is specifically designed for children.

“This trial has been extremely successful,” chief executive Mark Ferguson said.

Whilst the new formulation is designed for children, it was tested in eighty four healthy male and female adult volunteers.

Four incisions were cut under the arms of the volunteers, and they were treated in a double blind, placebo controlled study of the safety and efficacy of Juvista and Juvista Paediatric on scar appearance after 12 months.

Standardized photographs were taken and scars evaluated over regular intervals by a panel of experts.

According to Ferguson, more than half of the wounds were deemed by the panel of experts to have been improved by Juvista.

More information on Juvista and other upcoming products such as Prevascar on the Renovo website. Original source of this article.